Comparative analysis of curative efficacy and prognostic factors across treatment modalities for early-stage hepatocellular carcinoma (BCLC 0/A)
World Journal of Gastrointestinal Oncology · 15.07.2026 · 18 (7)
DOI: 10.4251/wjgo.119136 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Gastrointestinal Oncology, online erschienen am 15.07.2026. Verfasst von Wen Zheng und 5 weiteren Autor:innen. Die Arbeit nennt 22 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND While the prognostic impact of radiofrequency ablation (RFA) vs liver resection (LR) remains controversial for Barcelona Clinic Liver Cancer (BCLC) stage 0/A hepatocellular carcinoma (HCC). AIM To comparatively analyze prognostic outcomes across therapeutic approaches. METHODS We conducted a multicenter retrospective analysis of treatment-naïve HCC patients meeting BCLC stage 0/A criteria at the First Affiliated Hospital of Shihezi University and Shandong Provincial Hospital between January 2012 and December 2022, stratifying patients into three therapeutic cohorts: LR monotherapy (LR; n = 30), RFA alone (RFA; n = 40), and combined therapy (LR plus adjuvant treatment; n = 32), with primary endpoints of five-year overall survival (OS), progression-free survival (PFS), and median survival time analyzed using Kaplan-Meier (K-M) methodology. RESULTS A total of 102 patients with HCC were included, and they were followed up until December 31, 2023. The follow-up rate was 100%. Treatment modalities significantly impacted five-year OS (P = 0.03). Cox regression confirmed both LR [hazard ratio (HR) = 0.297; 95% confidence interval (CI): 0.104-0.848; P = 0.02] and combination therapy (HR = 0.331; 95%CI: 0.118-0.931; P = 0.04) significantly reduced mortality risk versus RFA. Furthermore, K-M analysis demonstrated significant differences in OS among the three treatment modalities (RFA, LR, and combined treatment; log-rank test, P = 0.02), and the LR group exhibited significantly improved 5-year OS compared to the RFA group (P = 0.047). Similarly, significant differences in PFS were observed among the three treatment modalities (log-rank test, P = 0.009), and both the LR group (P = 0.049) and combined therapy group (P = 0.033) exhibited significantly longer PFS compared to the RFA group. CONCLUSION We recommend LR as the first-line therapeutic option for early-stage HCC, while advocating active pursuit of combination therapy regimens for high-risk early-stage HCC patients to obtain comparable survival outcomes with LR alone.
Zitieren
APA
Zheng, W., Lv, P., Zhu, Q., Zhang, Q., Yin, G., & Chen, W. (2026). Comparative analysis of curative efficacy and prognostic factors across treatment modalities for early-stage hepatocellular carcinoma (BCLC 0/A). World Journal of Gastrointestinal Oncology, 18(7). https://doi.org/10.4251/wjgo.119136
Vancouver
Zheng W, Lv P, Zhu Q, Zhang Q, Yin G, Chen W. Comparative analysis of curative efficacy and prognostic factors across treatment modalities for early-stage hepatocellular carcinoma (BCLC 0/A). World Journal of Gastrointestinal Oncology. 2026;18(7). doi:10.4251/wjgo.119136
BibTeX
@article{Zheng2026,
author = {Zheng, Wen and Lv, Ping and Zhu, Qiang and Zhang, Qing-Lin and Yin, Gang-Gang and Chen, Wei-Gang},
title = {Comparative analysis of curative efficacy and prognostic factors across treatment modalities for early-stage hepatocellular carcinoma (BCLC 0/A)},
journal = {World Journal of Gastrointestinal Oncology},
year = {2026},
volume = {18},
number = {7},
doi = {10.4251/wjgo.119136}
}
EUVIMED